This book offers a comprehensive overview of how to utilize the bioconvergence revolution to substantially enhance research productivity. It carefully addresses critical issues such as ethical dilemmas, collaborative dynamics, funding, and operational efficiency, complete with concrete examples of how to overcome these challenges. Historically, the natural world has served as a profound source of inspiration for technological innovation. The natural materials, structures, and processes found in organisms have facilitated numerous scientific advancements. Presently, the integration of nature with scientific research is intensified through convergence. The book explores this convergence as a multidisciplinary approach that leverages the synergies among digital technologies, material sciences, and biotechnology, aiming to significantly accelerate and broaden the scope of scientific breakthroughs.
This volume provides a scholarly account of the emerging opportunities catalyzed by bioconvergence, emphasizing the necessity for rigorous ethical frameworks and standards as biotechnologies and digital tools converge to explore new frontiers. It delves into the challenges of financing scientific advancement and articulates how funding underpins multidisciplinary research efforts. Featuring Israel as a leader in this revolutionary field, the book meticulously outlines the Israeli ecosystem as a paradigm of innovation in bioconvergence. This work possesses a broad interdisciplinary appeal, making it an essential resource for researchers in both industry and academia, as well as for scholars and funding bodies dedicated to the advancement of science.
Dr. Nina Siragusa holds the position of Strategy Business Lead at Merck Healthcare KGaA. Trained as a scientist with a doctorate in biology, Dr. Siragusa has dedicated her academic career to the flourishing field of bioconvergence, exploring a diverse array of topics. Her extensive research background encompasses fungal biology, delving into areas such as natural product research, molecular biology, and advanced sequencing and big data analysis across prestigious institutions in Europe and Yale University in the United States.
In 2016, Dr. Siragusa transitioned to Merck KGaA, where she assumed the role of Innovation Expert. In this capacity, she spearheaded the biotechnology segment of a pioneering synthetic biology project, once again synergizing digital technology and engineering within the framework of bioconvergence. Prior to her current role in the Healthcare Business unit, she was appointed Chief of Staff to Merck's Chief Science and Technology Officer, Laura Matz. During this period, Dr. Siragusa played a pivotal role in advancing the bioconvergence mega-trend, further solidifying her reputation as a leader in the field.
André T. Nemat is founder and Managing Partner of the Institute for Digital Transformation in Healthcare at Witten/Herdecke University, Germany. As a surgeon by training with an engineering background, he is an expert in the field of thoracic surgery. With a PhD from the University of Duesseldorf Germany, he has over 15 years of experience as chief physician and director of specialized lung-clinics.
Currently he acts as Executive Medical Director of the VKh.NRW. The "Virtual Hospital" is anchored in the Ministry of Health of the State of North Rhine-Westphalia and serves to transform the healthcare system by implementing digital innovations for comprehensive care. As a Boardmember of the International Data Spaces Association he focuses intensively on the added value of data-based innovation while preserving data sovereignty, on human digital twins in medicine and on digital ethics.
